ATTR-CM: Outpatient Heart Failure Worsening & Mortality Risk

A worsening of heart failure symptoms experienced by patients while not hospitalized – specifically, a require for increased diuretic medication at home – is a significant predictor of mortality in individuals with transthyretin amyloid cardiomyopathy (ATTR-CM), even those receiving treatment with tafamidis. This finding, published in December 2024, underscores the importance of close monitoring for subtle changes in heart failure status for those living with this rare and progressive disease.

Understanding Transthyretin Amyloid Cardiomyopathy

Transthyretin amyloid cardiomyopathy (ATTR-CM) occurs when a misfolded protein, transthyretin, builds up in the heart muscle, leading to stiffening and eventual heart failure. The condition can be hereditary or “wild-type,” meaning it develops without a known genetic cause. Symptoms often mimic those of other heart conditions, making diagnosis challenging. These can include shortness of breath, fatigue, swelling in the legs and ankles and irregular heartbeat. Recent data suggests that even with treatment using tafamidis – a medication designed to stabilize the transthyretin protein – a substantial proportion of patients (around 40%) may still die within four years of diagnosis.

The Study: Outpatient Diuretic Intensification as a Warning Sign

Researchers at Columbia University Irving Medical Center retrospectively analyzed data from 303 ATTR-CM patients who were being treated with tafamidis. The study, published in the journal PubMed, focused on identifying factors associated with mortality. They specifically looked at “worsening heart failure” (WHF) events, categorizing them as either hospitalizations for heart failure or a sustained increase in the dose of loop diuretics – medications that facilitate the body eliminate excess fluid.

The key finding was that patients who experienced WHF characterized by outpatient diuretic intensification (ODI) – meaning their doctor increased their diuretic dose and they continued to need it for over a month – had significantly higher mortality rates. Specifically, the mortality rate was 17.7 per 100 person-years for those with ODI, compared to 29.8 per 100 person-years for those hospitalized for heart failure, and 5.0 per 100 person-years for those who experienced no WHF events. This suggests that needing to increase diuretic medication at home is a particularly concerning signal.

What Does This Signify for Patients?

This research doesn’t mean that tafamidis isn’t effective. Rather, it highlights the need for proactive monitoring and management of ATTR-CM, even in patients who are already receiving treatment. The study suggests that a seemingly tiny change – needing a higher dose of a water pill – can be an early indicator of disease progression and a heightened risk of death.

It’s important to understand that correlation does not equal causation. While the study demonstrates a strong association between ODI and mortality, it doesn’t prove that increasing diuretics causes a higher risk of death. It’s likely that ODI is a marker of underlying disease worsening that is, in itself, driving the increased mortality.

Beyond Tafamidis: The Search for Better Treatments

The findings come as the medical community continues to seek more effective treatments for ATTR-CM. Tafamidis was a significant step forward, being the first approved medication for the condition. More recently, acoramidis (Attruby and Beyonttra) has also been approved, offering another option for stabilizing the transthyretin protein. Researchers emphasize that further drug development is crucial to improve outcomes for patients.

NT-proBNP and Other Prognostic Markers

The study reinforces the importance of monitoring biomarkers like NT-proBNP, a hormone released by the heart in response to stress. Increases in NT-proBNP, along with ODI, have been identified as markers of disease progression in ATTR-CM patients. Research indicates that tracking these markers can help clinicians identify patients at higher risk and potentially adjust treatment strategies.

What Comes Next: Refining Risk Stratification

The current focus is on refining risk stratification for ATTR-CM patients. Researchers are working to identify combinations of biomarkers, clinical factors, and imaging findings that can accurately predict disease progression and mortality. This will allow for more personalized treatment approaches, tailoring interventions to the specific needs of each patient. Further studies are also needed to evaluate the long-term effects of tafamidis and acoramidis, and to explore the potential of novel therapies. Ongoing clinical trials are investigating new approaches to targeting the underlying causes of ATTR-CM and improving patient outcomes.